AlphAIalphai — Financial news for AI agents
investing.comAUG 282 min read$MDT

TD Cowen raises Medtronic stock price target to $110 on growth outlook

TD Cowen raised its price target for Medtronic (NYSE:MDT) to $110.00, citing expected revenue and earnings growth. The company's first-quarter fiscal 2027 guidance includes a 6.25% organic revenue growth. Medtronic also completed a $650 million acquisition and faces a $88 million hernia mesh trial verdict.

Original reporting
investing.com
Published Aug 28, 2026, 10:20 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 29, 2026, 4:29 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefMergers & acquisitions
Primary signal
$MDT
Bullish
medium confidence
Mentioned
$MDT
Relevance
7/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$MDTBullishMed
01

Why it matters

The price target raise and acquisition provide a fresh catalyst for the stock.

02

Market read

Analyst upgrade and strategic acquisition could drive MDT higher.

03

What to watch

Potential regulatory scrutiny of the SPR Therapeutics deal.

Relevance 7/10Novelty 6/10Timing: today

Background

Analyst coverage update and acquisition announcement for Medtronic.

Company-level read

Ticker impact

$MDTBullishMedium confidence
Context

TD Cowen raised its price target to $110 and Medtronic completed a $650M acquisition of SPR Therapeutics.

Expected impact

Potential price appreciation toward the new $110 target.

Evidence & confidence

Higher target and strategic acquisition could boost earnings outlook.

Market effects

Sector

Medical device sector may see increased M&A activity.

Regional

U.S. healthcare stocks could benefit.

Global

Limited to Medtronic and its peers.

Counterpoint

What could challenge this read

The acquisition may strain cash flow and integration risk could offset upside.

Key entities

  • company
    Medtronic

    Medical device manufacturer (ticker MDT).

  • analyst
    TD Cowen

    Equity research firm raising price target.

  • company
    SPR Therapeutics

    Target of Medtronic's $650M acquisition.

Read at source← All news

Related articles

AUG 28
$ABTMedAI 8/10

This Week at FDA: HHS considering new FDA posts, FDA approves slew of firsts, and more

The Trump administration may add two FDA deputy commissioner roles. FDA approved first-of-kind treatments from Revolution Medicines (Rasonque for pancreatic cancer), Priovant Therapeutics (Lisraya for dermatomyositis), and Janssen Biotech (Imaavy for wAIHA). Abbott's Libre Duo 10 Day received de novo authorization for a dual glucose and ketone monitoring system. FDA issued alerts for Abiomed, Medtronic, and Boston Scientific devices, and recalls for Boston Scientific and AVID Medical products.

raps.org3 min
AUG 28
$MDTHighAI 9/10

Medtronic acquires SPR for $650 million to expand pain portfolio

Medtronic acquired SPR Therapeutics for $650 million in cash, adding the SPRINT PNS System to its pain therapy portfolio. The system offers non-opioid, short-term pain relief with 60% of patients achieving significant pain reduction. The deal is expected to be minimally dilutive to Medtronic's EPS in FY27 and neutral to accretive thereafter, aligning with its strategy to expand in high-growth areas.

scanx.trade2 min
AUG 23
$DHRMedAI 8/10

Danaher vs. Medtronic: Which Healthcare Recovery Story Has More Upside?

Danaher (DHR) and Medtronic (MDT) report recovery signs. DHR benefits from life sciences demand, with bioprocessing orders growing mid-teens. MDT shows highest annual revenue growth in 10 years, with Q4 revenue at $9.8B and FY26 at $36.4B. MDT's cardiac segment grew 78% globally, driven by cardiac ablation solutions. Both companies face challenges, with MDT's growth concentrated in a few platforms and DHR's revenue delayed into next year.

yahoo.com3 min
AUG 23
$MDTMedAI 8/10

Medtronic vs. Tenet Healthcare: Which Healthcare Stock Offers Better Long-Term Growth?

Medtronic (MDT) and Tenet Healthcare (THC) present distinct growth prospects. MDT reported its highest annual revenue growth in a decade, driven by cardiac ablation solutions and investments in innovation. THC saw a 52.2% increase in adjusted EPS and 6.8% revenue growth, with margin expansion in hospitals. Investors must choose between MDT's innovation-led recovery and THC's operational improvements.

yahoo.com3 min